- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 16.04. | Reducing disparities in healthcare through shared decision-making | ||
| 15.04. | NHS programme to give melanoma patients fast-track access to skin cancer vaccine | ||
| 15.04. | J&J's subcutaneous Darzalex regimen approved by EC for newly diagnosed multiple myeloma | ||
| 15.04. | Amgen shares positive phase 3 results for Imdelltra in small cell lung cancer | ||
| 15.04. | Point.1: Your first point in people-centred precision marketing | ||
| 14.04. | AstraZeneca's Truqap recommended by NICE to treat advanced breast cancer | ||
| 14.04. | BMS receives FDA approval for immunotherapy combination in liver cancer | ||
| 14.04. | Roche's Columvi granted EC approval to treat diffuse large B-cell lymphoma | ||
| 14.04. | How HCPs and patients are partnering to transform care | ||
| 11.04. | Novartis to invest $23bn into US-based infrastructure over next five years | ||
| 11.04. | Johnson & Johnson's subcutaneous Rybrevant granted EC approval to treat NSCLC | ||
| 11.04. | Bayer's Vitrakvi receives full FDA approval for NTRK gene fusion-positive tumours | ||
| 10.04. | AstraZeneca/Daiichi Sankyo's Datroway approved by EC to treat breast cancer | ||
| 10.04. | Sanofi's tolebrutinib shown to delay MS disability progression in phase 3 study | ||
| 10.04. | Compass Therapeutics' tovecimig shows promise in phase 2/3 biliary tract cancer study | ||
| 09.04. | BMS granted FDA approval for immunotherapy combination in colorectal cancer | ||
| 09.04. | AbbVie's Rinvoq receives EC approval to treat adults with giant cell arteritis | ||
| 09.04. | Johnson & Johnson shares positive late-stage results for Tremfya in psoriatic arthritis | ||
| 08.04. | Eli Lilly and Sangamo Therapeutics enter CNS disease partnership worth over $1.4bn | ||
| 08.04. | Ipsen's Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis | ||
| 08.04. | Naturally occurring peptide shows promise as potential psoriasis treatment | ||
| 07.04. | GSK and ABL Bio enter neurodegenerative disease agreement worth over £2bn | ||
| 07.04. | AstraZeneca's Imfinzi regimen receives EC approval to treat resectable NSCLC | ||
| 07.04. | J&J's Stelara granted EC approval to treat Crohn's disease in paediatric patients | ||
| 07.04. | The AI advantage: seven steps to augmented pharma brand planning |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
